Abstract | OBJECTIVES: DESIGN: We randomly assigned 49 children with PR to receive either azithromycin (12 mg/kg per day, up to a maximum of 500 mg/day) for 5 days or a similar-appearing placebo. Study physicians were blinded to patients' treatment type. Two pediatricians had to agree on the diagnosis of PR before patients could be enrolled. Subjects were seen at follow-up visits 1, 2, and 4 weeks after starting treatment. OUTCOME MEASURES: We measured the appearance of new lesions and resolution of lesions. RESULTS: Rates of cure and of partial resolution were similar in the azithromycin and placebo groups. CONCLUSION:
|
Authors | Ahdi Amer, Howard Fischer |
Journal | Pediatrics
(Pediatrics)
Vol. 117
Issue 5
Pg. 1702-5
(May 2006)
ISSN: 1098-4275 [Electronic] United States |
PMID | 16651327
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Erythromycin
- Azithromycin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Azithromycin
(therapeutic use)
- Child
- Child, Preschool
- Double-Blind Method
- Erythromycin
(therapeutic use)
- Female
- Humans
- Male
- Pityriasis Rosea
(drug therapy)
|